Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today)
Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today)
Inspire Pharmaceuticals Inc.'s decision to discontinue development of the oral antihistamine bilastine for allergic rhinitis was "no surprise" to Cowen & Co. analyst Ian Sanderson. (BioWorld Today)
Inspire Pharmaceuticals Inc.'s decision to discontinue development of the oral antihistamine bilastine for allergic rhinitis was "no surprise" to Cowen & Co. analyst Ian Sanderson. (BioWorld Today)
